Insulin aspart

Control-IQ Technology Continues to Demonstrate Positive and Sustained Real-World Benefits Across Diverse Cohorts of People with Diabetes

Retrieved on: 
Monday, June 6, 2022
Diabetes, Health, Medical Devices, Real-World Evidence, Tandem Diabetes Care, Hearing, Diabetes, Behavioural sciences, Safety, ADA, Veni, vidi, vici, CGM, Software, Hydroxycarbamide, Meal, GMI, Insulin pump, Dialysis, American Diabetes Association, TIR, Motivation, Patient, CT, Glycated hemoglobin, Insulin, CLIO, MS, Technology, Medical director, GlySens ICGM, Pregnancy, NASDAQ, ACE, Sleep, Twitter, MD, Insulin aspart, Doctor of Education, Insulin lispro, Poster, Multi, MRI, Person, Tandem, Pharmaceutical industry, Medical device, Adult, White

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2 insulin pump with Control-IQ technology.

Key Points: 
  • Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2 insulin pump with Control-IQ technology.
  • Psychosocial benefits of Control-IQ technology were experienced by all ethnic cohorts.
  • Multiple daily injection users with relatively high HbA1c values initiating Control-IQ technology showed dramatic and sustained glycemic improvements.
  • Psychosocial Benefits of using the t:slim X2 Insulin Pump with Control-IQ technology: Long-term Outcomes from a Multi-ethnic Adult Cohort with Type 1 Diabetes.

Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative

Retrieved on: 
Thursday, June 2, 2022
Health, FDA, Medical Devices, Diabetes, Clinical Trials, Research, Science, Insulin analog, Company, Research, Knowledge, Prediabetes, Pharmacokinetics, Pharmacology, Physician, FDA, Insulin, Biosimilar, Diabetes, Obesity, Clinical trial, Insulin lispro, Drug development, Civica Rx, AP, Safety, Insulin aspart, Pancreas, Pharmaceutical industry, Insulin glargine, Civica, Profil

Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.

Key Points: 
  • Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.
  • Profil has conducted over 30 biosimilar insulin trials and is the leading clinical research organization for studies related to diabetes.
  • With its extensive experience and quality track record, Profil is the ideal clinical trial partner for Civica.
  • More information on Civica and its affordable insulin initiative, including commentary from partners and a fact sheet, can be found at https://civicainsulin.org .

Real-World Evidence Confirms Immediate and Ongoing Performance of the t:slim X2 Insulin Pump with Control-IQ Technology in Children and Adults

Retrieved on: 
Wednesday, April 27, 2022
Diabetes, Health, Medical Devices, People, Glycated hemoglobin, CLIO, Quality of life, CGM, NASDAQ, Sleep, Hearing, Safety, Insulin aspart, Pregnancy, CT, ATTD, Meal, Manning M. Knapp, Treatment, Implementation, Technology, Population, Poster, Start, Hydroxycarbamide, Honda advanced technology, Pediatrics, Twitter, Doctor of Education, MDI, Type 1, Conference, MS, Adoption, Insulin, Pros, Veni, vidi, vici, Dialysis, Tandem, Medicine, International Conference on Information Systems Security and Privacy, MRI, Department, MD, Tandem Diabetes Care, Insulin lispro, Behavioural sciences, Hospital, Initiation, Pharmaceutical industry, Medical device, Dentistry, Diabetes, System

Separate from the CLIO study, researchers retrospectively studied the first 90 days of pump activation in MDI users transitioning to the t:slim X2 pump with Control-IQ technology.

Key Points: 
  • Separate from the CLIO study, researchers retrospectively studied the first 90 days of pump activation in MDI users transitioning to the t:slim X2 pump with Control-IQ technology.
  • The results showed that 95 percent of MDI users successfully initiated Control-IQ technology within 14 days of pump start.
  • Long-Term Improvements In Patient-Reported Outcomes Irrespective of Baseline Glycemic Control and Previous Insulin Delivery Method with the t:Slim X2 Pump with Control-IQ Technology.
  • Important Safety Information: The t:slim X2 insulin pump with Control-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Control-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately).

JDRF Announces Support of Civica to Manufacture and Distribute Low-Cost Insulin

Retrieved on: 
Thursday, March 3, 2022
Mayo Clinic, Automated insulin delivery systems, Cranial nerve disease, Critical care, Research, Human, HCA Healthcare, Blue Cross, Industry, Diet, Hospital, Leona, Death, Twitter, Insulin, Eye, Insulin lispro, Civica, Trinity, SSM Health, Insulin aspart, Program, JDRF, Volunteering, Trinity Health, Efficiency, CommonSpirit Health, Intermountain Healthcare, Multimedia, Food, Private sector, Pharmacy, Type 1 diabetes, Kidney, Immune system, Health, Arnold Ventures LLC, BCBS, Pancreas, Blue Cross Blue Shield Association, Pharmaceutical industry, T1D, Transcare EMS, Instagram, Kaiser Permanente, Insulin glargine, Facebook

The project will manufacture and distribute three low-cost biosimilar insulin options to enable anyone to purchase insulin at no more than $30/vial and $55/box of five pens, regardless of insurance status.

Key Points: 
  • The project will manufacture and distribute three low-cost biosimilar insulin options to enable anyone to purchase insulin at no more than $30/vial and $55/box of five pens, regardless of insurance status.
  • "The Civica insulin development project is a tremendous step forward to make insulin accessible for all, regardless of insurance status, and address a national crisis," saidAaron Kowalski, Ph.D., JDRF CEO.
  • Hospital advisorsdoctors and pharmacistsprioritize the essential medicines Civica provides for use in acute and critical care, emergency rooms, and surgery.
  • Civica has since launched CivicaScript, focused on lowering prices at the pharmacy counter and The Civica Foundation, dedicated to fostering philanthropic support for manufacturing and distributing essential medicines.

Capillary Biomedical Receives FDA Approval to Begin Pivotal Trial of Its SteadiFlow Seven-Day-Wear Infusion Set Technology

Retrieved on: 
Wednesday, January 19, 2022
FDA, Diabetes, Medical Devices, Health, Clinical Trials, Ageing, Patient, Technology, Insulin, Inflammation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Extended-wear hearing aid, IDE, Pain, Cannula, Skin, Diabetes, Insulin aspart, CRO, Quality of life, Doctor of Philosophy, MD, Food, FDA, Maintenance, Medical device, Insulin lispro

Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to start a pivotal trial for the assessment of its SteadiFlow seven-day-wear infusion set technology.

Key Points: 
  • Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to start a pivotal trial for the assessment of its SteadiFlow seven-day-wear infusion set technology.
  • CapBios SteadiSet infusion set, powered by its SteadiFlow technology platform, is designed to increase the wear time of insulin infusion sets by addressing the common causes of infusion site failure.
  • With this pivotal trial we are pleased to be taking a significant next step in the evolution of our SteadiFlow infusion set, said CapBio CEO Paul Strasma.
  • The Companys first product, the SteadiSet infusion set featuring SteadiFlow technology, is designed to improve the comfort, reliability and predictability of insulin pump therapy.

US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026: First FDA Approved Interchangeable Biosimilar Insulin Cost & Dosage Insight - ResearchAndMarkets.com

Retrieved on: 
Monday, August 23, 2021
Medical Devices, Health, Insulin lispro, Publication, FDA, Insulin, Research, Government, Private sector, Growth, Patent, Insulin aspart, Pharmaceutical industry, Generic drug

The "US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The biosimilar insulin is processed in a way that it almost mimics the action of the original insulin product.
  • Approval of Semglee as first interchangeable insulin biosimilar is believed to act as a revolutionary step for the US insulin biosimilar market, which simplifies the path of approval for other investigational biosimilars.
  • The report also involves the comparative price analysis along with the clinical trends, market drivers and possible challenges related to US insulin biosimilar market.

TempraMed's VIVI Cap 1 is changing the way people who inject insulin live their lives

Retrieved on: 
Friday, July 16, 2021
Clinical medicine, Branches of biology, Organ systems, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Type 1 diabetes, Injector pen, Insulin pump, Insulin aspart

TempraMed's recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention.

Key Points: 
  • TempraMed's recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention.
  • From the point of manufacturing up until it is used, insulin needs to be kept between 36 to 46F.
  • During use, insulin does not have to be refrigerated but it should stay below 86F and should not freeze.
  • Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised.

Global Insulin Pumps Industry

Retrieved on: 
Monday, April 20, 2020
Endocrine system, Eli Lilly and Company, Medicine, Hormones, RTT, Peptide hormones, Recombinant proteins, Diabetes, Insulin pump, Insulin, Insulin aspart

US Insulin Pumps Market Share (in %) by Company: 2020 & 2025

Key Points: 
  • US Insulin Pumps Market Share (in %) by Company: 2020 & 2025
    Projections in US$ Million by Type: 2018 to 2025
    Table 17: Insulin Pumps Market in the United States by Type:
    in US$ Million by Type: 2018 to 2025
    Table 21: Insulin Pumps Market in Canada: Percentage Share
    Breakdown of Sales by Type for 2009, 2019, and 2025
    Table 22: Japanese Market for Insulin Pumps: Annual Sales
    Table 23: Insulin Pumps Market in Japan: Historic Sales
    Table 24: Japanese Insulin Pumps Market Share Analysis by Type:
    Table 27: Chinese Insulin Pumps Market by Type: Percentage
    Breakdown of Sales for 2009, 2019, and 2025
    Table 29: Insulin Pumps Market in Europe: A Historic Market
    in US$ Million by Type: 2018-2025
    Table 34: Insulin Pumps Market in France by Type: Estimates and
    Table 36: French Insulin Pumps Market Share Analysis by Type:
    Table 37: Insulin Pumps Market in Germany: Recent Past, Current
    Table 39: German Insulin Pumps Market Share Breakdown by Type:
    Table 42: Italian Insulin Pumps Market by Type: Percentage
    Breakdown of Sales for 2009, 2019, and 2025
    Table 43: United Kingdom Market for Insulin Pumps: Annual Sales
    Table 44: Insulin Pumps Market in the United Kingdom: Historic
    Forecasts in US$ Million by Type: 2018-2025
    Table 49: Insulin Pumps Market in Asia-Pacific by Type:
    in US$ Million by Type: 2009-2017
    Forecasts in US$ Million by Type: 2018 to 2025
    Table 54: Insulin Pumps Market in Rest of World: Percentage
    Share Breakdown of Sales by Type for 2009, 2019, and 2025

FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes

Retrieved on: 
Tuesday, October 22, 2019
Endocrine system, Organ systems, Medicine, RTT, Eli Lilly and Company, Peptide hormones, Recombinant proteins, Insulin aspart, Insulin pump, Insulin, Diabetes management, Diabetes

5 Fiasp has been shown to be well-tolerated and effective in pumps releasing steady doses throughout the day and mealtime doses during meals.

Key Points: 
  • 5 Fiasp has been shown to be well-tolerated and effective in pumps releasing steady doses throughout the day and mealtime doses during meals.
  • Fiasp is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.
  • The Fiasp label expansion to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes was based on data from onset 5, a randomised, multicenter, multinational trial, which investigated the efficacy and safety of continuous subcutaneous insulin infusion of Fiasp compared to NovoLog in adults with type 1 diabetes.5
    What is Fiasp (insulin aspart injection) 100 U/mL?
  • Fiasp is a man-made insulin used to control high blood sugar in adults with diabetes mellitus.

China's Insulin Aspart Market 2013-2022: Disease Overview, Sales, Prices, Progress & Market Prospects

Retrieved on: 
Friday, November 2, 2018
Endocrine system, Peptide hormones, Recombinant proteins, Medicine, Endocrinology, Eli Lilly and Company, Diabetes, Insulin analog, Insulin aspart, Insulin, Novo Nordisk

On the basis of Insulin Aspart, Novo Nordisk developed premixed insulin aspart containing soluble insulin aspart and protaminated insulin aspart of various proportions.

Key Points: 
  • On the basis of Insulin Aspart, Novo Nordisk developed premixed insulin aspart containing soluble insulin aspart and protaminated insulin aspart of various proportions.
  • 2005, NovoMix 30 (30% soluble insulin aspart and 70% protaminated insulin aspart), the first premixed insulin analog, was launched in China.
  • Because there are high technical barriers against the imitation of Insulin Aspart, by Oct. 2018, China's Insulin Aspart market is monopolized by Novo Nordisk's Insulin Aspart (NovoRapid).
  • 2 Sales of Insulin Aspart in China, 2013-2017
    2.3 Sales of Insulin Aspart by Dosage Form in China, 2013-2017
    3 Analysis on Major Insulin Aspart Manufacturers in China, 2013-2017
    4 Prices of Insulin Aspart in China, 2017-2018
    5 Prospect of China's Insulin Aspart Market, 2018-2022
    Did you know that we also offer Custom Research?